Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
First Affiliated Hospital of Zhengzhou University · Shanghai University · +17 more institutions
Abstract
A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or…
Citation impact
- FWCI
- 97.08
- Percentile
- 100%
- References
- 29
Authors
38- ZLZikuan LengCorresponding
First Affiliated Hospital of Zhengzhou University, Shanghai University
- RZRongjia Zhu
Chinese Academy of Medical Sciences & Peking Union Medical College
- WHWei Hou
Capital Medical University, Beijing YouAn Hospital
- YFYingmei Feng
Capital Medical University, Beijing YouAn Hospital
- YYYanlei Yang
Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital
Topics & keywords
- Medicine
- Cytokine storm
- Pneumonia
- Transplantation
- Mesenchymal stem cell
- Immunology
- Coronavirus
- Immune system
- Good health and well-being
Funding
- NNNational Natural Science Foundation of ChinaAwards: 81700782, 81672313, 81700782, 81971324, 2017-I2M-3-007, 81972523, 81672313, 81771349, 2018YFE0114200
- HEHigher Education Discipline Innovation ProjectAward: B18007
- NKNational Key Research and Development Program of ChinaAwards: 2017-I2M-3-007, 2018YFE0114200, 81771349